| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | IC2574G | |||
| Carrier Free | AF2574-SP | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier Free | MAB2574-SP | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| HRP | NBP2-79416-5Plates | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-90228-50ul | |||
![Western Blot: ILT6/CD85e/LILRA3 Antibody (2E9) [H00011026-M01] - Analysis of LILRA3 expression in transfected 293T cell line by LILRA3 monoclonal antibody (M01), clone 2E9.Lane 1: LILRA3 transfected lysate(50.485 KDa).Lane 2: Non-transfected lysate.](http://images.novusbio.com/fullsize/ILT6-CD85e-LILRA3-Antibody-2E9-Western-Blot-H00011026-M01-img0002.jpg "Western Blot: ILT6/CD85e/LILRA3 Antibody (2E9) [H00011026-M01] - Analysis of LILRA3 expression in transfected 293T cell line by LILRA3 monoclonal antibody (M01), clone 2E9.Lane 1: LILRA3 transfected lysate(50.485 KDa).Lane 2: Non-transfected lysate.")
![Western Blot: ILT6/CD85e/LILRA3 Antibody [NBP1-98549] - Human OVCAR-3 Lane A: Primary Antibody Lane B: Primary Antibody + Blocking Peptide. Primary Antibody Concentration: 1.0 ug/mL. Peptide Concentration: 2.0 ug/mL lysate. Quantity: 25 ug/lane.](http://images.novusbio.com/fullsize/ILT6-CD85e-LILRA3-Antibody-Western-Blot-NBP1-98549-img0004.jpg "Western Blot: ILT6/CD85e/LILRA3 Antibody [NBP1-98549] - Human OVCAR-3 Lane A: Primary Antibody Lane B: Primary Antibody + Blocking Peptide. Primary Antibody Concentration: 1.0 ug/mL. Peptide Concentration: 2.0 ug/mL lysate. Quantity: 25 ug/lane.")
![Western Blot: ILT6/CD85e/LILRA3 Antibody [NBP1-98549] - Antibody Dilution: 1.0ug/ml Sample Tissue: Human Kidney.](http://images.novusbio.com/fullsize/ILT6-CD85e-LILRA3-Antibody-Western-Blot-NBP1-98549-img0003.jpg)
![Western Blot: ILT6/CD85e/LILRA3 Antibody [NBP2-19351] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with LILRA3 antibody diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.](http://images.novusbio.com/fullsize/ILT6-CD85e-LILRA3-Antibody-Western-Blot-NBP2-19351-img0005.jpg "Western Blot: ILT6/CD85e/LILRA3 Antibody [NBP2-19351] - Non-transfected (-) and transfected (+) 293T whole cell extracts (30 ug) were separated by 10% SDS-PAGE, and the membrane was blotted with LILRA3 antibody diluted at 1:2000. The HRP-conjugated anti-rabbit IgG antibody (NBP2-19301) was used to detect the primary antibody.")
![Immunohistochemistry-Paraffin: ILT6/CD85e/LILRA3 Antibody [NBP2-19351] - Paraffin-embedded colon carcinoma. LILRA3 antibody [N2C2], Internal dilution: 1:250.](http://images.novusbio.com/fullsize/ILT6-CD85e-LILRA3-Antibody-Immunohistochemistry-Paraffin-NBP2-19351-img0003.jpg)
![Western Blot: LILRA3 Overexpression Lysate (Adult Normal) [NBL1-12525] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for LILRA3.](http://images.novusbio.com/fullsize/LILRA3-Overexpression-Lysate-Adult-Normal-Western-Blot-NBL1-12525-img0002.jpg "Western Blot: LILRA3 Overexpression Lysate (Adult Normal) [NBL1-12525] Left-Empty vector transfected control cell lysate (HEK293 cell lysate); Right -Over-expression Lysate for LILRA3.")
![Sandwich ELISA: ILT6/CD85e/LILRA3 Antibody Pair [HRP] [NBP2-79416] - This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.](http://images.novusbio.com/fullsize/ILT6-CD85e-LILRA3-Antibody-Pair-[HRP]-Sandwich-ELISA-NBP2-79416-img0001.jpg "Sandwich ELISA: ILT6/CD85e/LILRA3 Antibody Pair [HRP] [NBP2-79416] - This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.")
![Flow Cytometry: ILT6/CD85e/LILRA3 Antibody (060) [NBP2-90228] - Flow cytometric analysis of Human LILRA3(CD85e) expression on human whole blood monocytes. The cells were treated according to manufacturer's manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human LILRA3(CD85e), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable monocytes.](http://images.novusbio.com/fullsize/ILT6-CD85e-LILRA3-Antibody-060-Flow-Cytometry-NBP2-90228-img0001.jpg "Flow Cytometry: ILT6/CD85e/LILRA3 Antibody (060) [NBP2-90228] - Flow cytometric analysis of Human LILRA3(CD85e) expression on human whole blood monocytes. The cells were treated according to manufacturer's manual (BD Pharmingen™ Cat. No. 554714), stained with purified anti-Human LILRA3(CD85e), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of viable monocytes.")
![ELISA: Human ILT6/CD85e/LILRA3 ELISA Kit (Colorimetric) [NBP3-39999] - Standard Curve Reference](http://images.novusbio.com/fullsize/nbp3-39999_human-ilt6-cd85e-lilra3-elisa-kit-colorimetric-2110202415371333.png "ELISA: Human ILT6/CD85e/LILRA3 ELISA Kit (Colorimetric) [NBP3-39999] - Standard Curve Reference")
![ELISA: Human ILT6/CD85e/LILRA3 - Ready-To-Use ELISA Kit (Colorimetric) [NBP3-40000] - Standard Curve Reference](http://images.novusbio.com/fullsize/nbp3-40000_human-ilt6-cd85e-lilra3-ready-to-use-elisa-kit-color-2110202415362381.png "ELISA: Human ILT6/CD85e/LILRA3 - Ready-To-Use ELISA Kit (Colorimetric) [NBP3-40000] - Standard Curve Reference")